JP2018507230A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2018507230A5 JP2018507230A5 JP2017546121A JP2017546121A JP2018507230A5 JP 2018507230 A5 JP2018507230 A5 JP 2018507230A5 JP 2017546121 A JP2017546121 A JP 2017546121A JP 2017546121 A JP2017546121 A JP 2017546121A JP 2018507230 A5 JP2018507230 A5 JP 2018507230A5
- Authority
- JP
- Japan
- Prior art keywords
- alkyl
- optionally substituted
- heteroalkyl
- acyl
- heteroacyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 125000000217 alkyl group Chemical group 0.000 claims description 207
- 125000004404 heteroalkyl group Chemical group 0.000 claims description 190
- 125000005843 halogen group Chemical group 0.000 claims description 184
- 125000003710 aryl alkyl group Chemical group 0.000 claims description 179
- 125000003118 aryl group Chemical group 0.000 claims description 177
- 125000002252 acyl group Chemical group 0.000 claims description 169
- 125000001072 heteroaryl group Chemical group 0.000 claims description 165
- 229910052760 oxygen Inorganic materials 0.000 claims description 142
- 125000004446 heteroarylalkyl group Chemical group 0.000 claims description 133
- 229910052717 sulfur Inorganic materials 0.000 claims description 120
- 125000001424 substituent group Chemical group 0.000 claims description 85
- 229910052799 carbon Inorganic materials 0.000 claims description 81
- 229910052739 hydrogen Inorganic materials 0.000 claims description 80
- 125000005842 heteroatom Chemical group 0.000 claims description 76
- 229910052736 halogen Inorganic materials 0.000 claims description 74
- -1 hydroxy, amino Chemical group 0.000 claims description 66
- 150000001875 compounds Chemical class 0.000 claims description 65
- 125000003342 alkenyl group Chemical group 0.000 claims description 59
- 150000002367 halogens Chemical class 0.000 claims description 54
- 125000004429 atom Chemical group 0.000 claims description 46
- 125000000304 alkynyl group Chemical group 0.000 claims description 44
- 150000003839 salts Chemical class 0.000 claims description 41
- 125000000623 heterocyclic group Chemical group 0.000 claims description 39
- 125000004450 alkenylene group Chemical group 0.000 claims description 27
- 125000004474 heteroalkylene group Chemical group 0.000 claims description 27
- 125000000592 heterocycloalkyl group Chemical group 0.000 claims description 27
- 125000005647 linker group Chemical group 0.000 claims description 27
- 125000001960 7 membered carbocyclic group Chemical group 0.000 claims description 14
- 229910052721 tungsten Inorganic materials 0.000 claims description 14
- 125000004433 nitrogen atom Chemical group N* 0.000 claims description 12
- 125000004430 oxygen atom Chemical group O* 0.000 claims description 12
- 125000004434 sulfur atom Chemical group 0.000 claims description 12
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 claims description 9
- 125000004122 cyclic group Chemical group 0.000 claims description 9
- 229910052757 nitrogen Inorganic materials 0.000 claims description 6
- 206010028980 Neoplasm Diseases 0.000 claims description 4
- 201000011510 cancer Diseases 0.000 claims description 4
- 210000004185 liver Anatomy 0.000 claims description 4
- 210000004369 blood Anatomy 0.000 claims description 2
- 239000008280 blood Substances 0.000 claims description 2
- 210000004556 brain Anatomy 0.000 claims description 2
- 210000001072 colon Anatomy 0.000 claims description 2
- 210000003128 head Anatomy 0.000 claims description 2
- 210000002216 heart Anatomy 0.000 claims description 2
- 239000001257 hydrogen Substances 0.000 claims description 2
- 210000003734 kidney Anatomy 0.000 claims description 2
- 210000004072 lung Anatomy 0.000 claims description 2
- 210000001165 lymph node Anatomy 0.000 claims description 2
- 210000003739 neck Anatomy 0.000 claims description 2
- 210000000496 pancreas Anatomy 0.000 claims description 2
- 210000002307 prostate Anatomy 0.000 claims description 2
- 125000001313 C5-C10 heteroaryl group Chemical group 0.000 claims 45
- 125000004649 C2-C8 alkynyl group Chemical group 0.000 claims 37
- 125000004648 C2-C8 alkenyl group Chemical group 0.000 claims 36
- 125000006832 (C1-C10) alkylene group Chemical group 0.000 claims 13
- 125000000896 monocarboxylic acid group Chemical group 0.000 claims 9
- 125000006374 C2-C10 alkenyl group Chemical group 0.000 claims 7
- 150000001732 carboxylic acid derivatives Chemical group 0.000 claims 4
- 125000002837 carbocyclic group Chemical group 0.000 claims 3
- 241000257303 Hymenoptera Species 0.000 claims 2
- 125000005549 heteroarylene group Chemical group 0.000 claims 2
- 239000000203 mixture Substances 0.000 claims 2
- 208000000453 Skin Neoplasms Diseases 0.000 claims 1
- 210000000481 breast Anatomy 0.000 claims 1
- 125000004435 hydrogen atom Chemical class [H]* 0.000 claims 1
- 150000002148 esters Chemical class 0.000 description 24
- 229940002612 prodrug Drugs 0.000 description 20
- 239000000651 prodrug Substances 0.000 description 20
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 17
- 125000002947 alkylene group Chemical group 0.000 description 14
- 150000001408 amides Chemical class 0.000 description 4
- 125000002843 carboxylic acid group Chemical group 0.000 description 4
- 238000000034 method Methods 0.000 description 3
- 101150046160 POL1 gene Proteins 0.000 description 2
- 101100117436 Thermus aquaticus polA gene Proteins 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 238000013518 transcription Methods 0.000 description 2
- 230000035897 transcription Effects 0.000 description 2
- 206010006187 Breast cancer Diseases 0.000 description 1
- 208000026310 Breast neoplasm Diseases 0.000 description 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 230000028706 ribosome biogenesis Effects 0.000 description 1
- 210000003491 skin Anatomy 0.000 description 1
- 239000012453 solvate Substances 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562128208P | 2015-03-04 | 2015-03-04 | |
| US62/128,208 | 2015-03-04 | ||
| PCT/US2016/020418 WO2016141042A2 (en) | 2015-03-04 | 2016-03-02 | Novel compositions, uses and methods for making them |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021014802A Division JP2021066741A (ja) | 2015-03-04 | 2021-02-02 | 新規な組成物、使用およびそれを作製するための方法 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2018507230A JP2018507230A (ja) | 2018-03-15 |
| JP2018507230A5 true JP2018507230A5 (OSRAM) | 2019-04-11 |
| JP6878288B2 JP6878288B2 (ja) | 2021-05-26 |
Family
ID=56848519
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017546121A Active JP6878288B2 (ja) | 2015-03-04 | 2016-03-02 | 新規な組成物、使用およびそれを作製するための方法 |
| JP2021014802A Pending JP2021066741A (ja) | 2015-03-04 | 2021-02-02 | 新規な組成物、使用およびそれを作製するための方法 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021014802A Pending JP2021066741A (ja) | 2015-03-04 | 2021-02-02 | 新規な組成物、使用およびそれを作製するための方法 |
Country Status (7)
| Country | Link |
|---|---|
| US (9) | US9758518B2 (OSRAM) |
| EP (1) | EP3300501A4 (OSRAM) |
| JP (2) | JP6878288B2 (OSRAM) |
| CN (1) | CN107567448B (OSRAM) |
| CA (1) | CA2978571C (OSRAM) |
| MX (1) | MX2017011116A (OSRAM) |
| WO (1) | WO2016141042A2 (OSRAM) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9758518B2 (en) | 2015-03-04 | 2017-09-12 | Pimera, Inc. | Compositions, uses and methods for making them |
| CN106588920B (zh) * | 2016-12-27 | 2018-10-30 | 云南大学 | 1,3-二氮杂环并[1,2-a]喹啉类化合物及其制备方法和抗肿瘤应用 |
| CN110709400A (zh) * | 2017-03-28 | 2020-01-17 | 皮梅拉股份有限公司 | Pol1抑制剂的新型晶体形式 |
| US20220105083A1 (en) * | 2019-01-29 | 2022-04-07 | Arizona Board Of Regents On Behalf Of The University Of Arizona | Uses of compounds having anti-hsv-1 activity |
| US10947253B2 (en) | 2019-08-05 | 2021-03-16 | Ankh Life Sciences Limited | Fused polycyclic dimers |
| US12129265B2 (en) | 2020-07-21 | 2024-10-29 | Ankh Life Sciences Limited | Therapeutic agents and uses thereof |
| US12173005B1 (en) | 2023-12-21 | 2024-12-24 | King Faisal University | Pyrimido[1′,6′:1,5]pyrazolo[4,3-b][1,7]naphthyridine compounds as CK2 inhibitors |
Family Cites Families (33)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US1042801A (en) | 1909-10-28 | 1912-10-29 | Isidor Kitsee | Protecting kinematographic films. |
| NL7709746A (nl) | 1976-09-09 | 1978-03-13 | Hoechst Ag | Werkwijze ter bereiding van benzimidazo-(1,2-a)-chi- nolinen. |
| DE2929414A1 (de) | 1979-07-20 | 1981-02-05 | Hoechst Ag | Pyrimido- eckige klammer auf 5',4' zu 5,6 eckige klammer zu -pyrido- eckige klammer auf 1,2-a eckige klammer zu -benzimidazole, verfahren zu ihrer herstellung und deren verwendung |
| DE3502689A1 (de) | 1985-01-26 | 1986-07-31 | Hoechst Ag, 6230 Frankfurt | Elektrophotographisches aufzeichnungsmaterial |
| DE19509043A1 (de) | 1995-03-03 | 1996-09-05 | Bayer Ag | Cyanierung von Doppelbindungssystemen |
| US5624677A (en) | 1995-06-13 | 1997-04-29 | Pentech Pharmaceuticals, Inc. | Controlled release of drugs delivered by sublingual or buccal administration |
| ES2260300T3 (es) * | 2000-10-03 | 2006-11-01 | Bristol-Myers Squibb Company | Compuestos tetraciclicos sustituidos con amino utiles como agentes antiinflamatorios y composiciones farmaceuticas que comprenden los mismos. |
| NZ543006A (en) | 2003-04-07 | 2009-03-31 | Cylene Pharmaceuticals Inc | Substituted quinobenzoxazine analogs |
| US7354916B2 (en) | 2003-04-07 | 2008-04-08 | Cylene Pharmaceuticals | Substituted quinobenzoxazine analogs |
| US7507727B2 (en) | 2003-04-07 | 2009-03-24 | Cylene Pharmaceuticals, Inc. | Substituted quinobenzoxazine analogs and methods of using thereof |
| MX2007003282A (es) | 2004-09-17 | 2007-10-16 | Cylene Pharmaceuticals Inc | Analogos de quinolona. |
| US7652134B2 (en) | 2004-09-17 | 2010-01-26 | Cylene Pharmaceuticals, Inc. | Methods for converting quinolone esters into quinolone amides |
| CA2604787A1 (en) | 2005-04-15 | 2006-10-26 | Cylene Pharmaceuticals, Inc. | Quinobenzoxazine analogs and methods of using thereof |
| PT1928887E (pt) | 2005-08-05 | 2015-02-12 | Senhwa Biosciences Inc | Métodos de preparação de análogos de quinolona |
| CA2621261C (en) | 2005-09-22 | 2014-05-20 | Incyte Corporation | Azepine inhibitors of janus kinases |
| US7998978B2 (en) | 2006-05-01 | 2011-08-16 | Pfizer Inc. | Substituted 2-amino-fused heterocyclic compounds |
| US20100063046A1 (en) | 2006-05-17 | 2010-03-11 | Whitten Jeffrey P | Tetracyclic imidazole analogs |
| WO2008156879A1 (en) | 2007-06-20 | 2008-12-24 | Universal Display Corporation | Blue phosphorescent imidazophenanthridine materials |
| PT3092901T (pt) | 2007-10-05 | 2020-05-21 | Senhwa Biosciences Inc | Análogos de quinolona e respetivos métodos relacionados |
| ATE542813T1 (de) | 2008-08-06 | 2012-02-15 | Pfizer | 6-substituierte 2- heterocyclylaminopyrazinverbindungen als chk-1- inhibitoren |
| JP5801193B2 (ja) | 2008-11-03 | 2015-10-28 | エルジー・ケム・リミテッド | 新しい含窒素複素環化合物およびそれを用いた有機電子素子 |
| US8124770B2 (en) | 2009-04-01 | 2012-02-28 | Beatriz Zayas | Fluorescent cellular markers |
| CN101781312B (zh) | 2009-12-30 | 2012-09-26 | 中国科学院广州生物医药与健康研究院 | 一种吲哚衍生物的合成方法 |
| US8637529B2 (en) | 2010-06-11 | 2014-01-28 | AbbYie Inc. | Pyrazolo[3,4-d]pyrimidine compounds |
| KR101567610B1 (ko) | 2010-11-04 | 2015-11-09 | 주식회사 엘지화학 | 신규한 질소 함유 헤테로환 화합물 및 이를 이용한 유기 전자 소자 |
| JP2014532626A (ja) | 2011-10-21 | 2014-12-08 | グラクソスミスクライン エルエルシー | 自然免疫応答を増強する化合物および方法 |
| KR101561730B1 (ko) | 2012-02-06 | 2015-10-22 | 주식회사 엘지화학 | 질소원소를 함유한 헤테로고리 유도체 및 이를 이용한 유기 전자 소자 |
| WO2015079411A1 (en) | 2013-11-28 | 2015-06-04 | Tel Hashomer Medical Research Infrastructure And Services Ltd. | Rna polymerase i inhibitors and uses thereof |
| US9758518B2 (en) | 2015-03-04 | 2017-09-12 | Pimera, Inc. | Compositions, uses and methods for making them |
| CA2948173C (en) | 2014-05-09 | 2018-06-19 | Pimera, Inc. | Quinoline compounds and uses thereof |
| CN106349244B (zh) | 2015-07-13 | 2018-07-27 | 首都医科大学 | 苯并咪唑并喹唑啉二甲氧苯氧乙酰-AA-OBzl，其合成，活性和应用 |
| CN119185322A (zh) | 2015-11-20 | 2024-12-27 | 生华生物科技股份有限公司 | 用于治疗癌症的四环喹诺酮类似物组合疗法 |
| CN110709400A (zh) | 2017-03-28 | 2020-01-17 | 皮梅拉股份有限公司 | Pol1抑制剂的新型晶体形式 |
-
2015
- 2015-11-06 US US14/935,155 patent/US9758518B2/en active Active
-
2016
- 2016-03-02 MX MX2017011116A patent/MX2017011116A/es unknown
- 2016-03-02 CN CN201680022357.7A patent/CN107567448B/zh active Active
- 2016-03-02 CA CA2978571A patent/CA2978571C/en active Active
- 2016-03-02 EP EP16759401.9A patent/EP3300501A4/en not_active Withdrawn
- 2016-03-02 US US15/555,024 patent/US10975076B2/en active Active
- 2016-03-02 WO PCT/US2016/020418 patent/WO2016141042A2/en not_active Ceased
- 2016-03-02 JP JP2017546121A patent/JP6878288B2/ja active Active
-
2017
- 2017-04-11 US US15/485,106 patent/US9951066B2/en active Active
- 2017-07-27 US US15/661,770 patent/US10590134B2/en active Active
-
2018
- 2018-01-08 US US15/864,965 patent/US10442801B2/en active Active
-
2019
- 2019-06-03 US US16/430,129 patent/US10745403B2/en active Active
-
2020
- 2020-01-10 US US16/739,354 patent/US11618752B2/en active Active
- 2020-07-09 US US16/925,220 patent/US11623928B2/en active Active
-
2021
- 2021-02-02 JP JP2021014802A patent/JP2021066741A/ja active Pending
- 2021-03-17 US US17/204,459 patent/US11866438B2/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2018507230A5 (OSRAM) | ||
| JP2019524883A5 (OSRAM) | ||
| JOP20210001A1 (ar) | مشتقات 3-(5- هيدروكسي -1- أوكسو أيزو إندولين -2- يل) بيبريدين -2، 6- دايون واستخدامها لمعالجة أمراض مرتبطة ببروتين ذات أصبع الزنك من عائلة (ikaros 2 (ikzf2 | |
| JP2011132222A5 (OSRAM) | ||
| JP5576485B2 (ja) | 新生物疾患又は自己免疫疾患を処置するためのプロドラッグとしてのフラザノベンゾイミダゾール | |
| MX2021013472A (es) | Moduladores de thr-? y metodos de uso de estos. | |
| JP2015532295A5 (OSRAM) | ||
| JP2020502049A5 (OSRAM) | ||
| CY1118390T1 (el) | Θεραπευτικος παραγων για τη φλεγμονωδη νοσο του εντερου | |
| JP2019529444A5 (OSRAM) | ||
| JP2014503574A5 (OSRAM) | ||
| JP2019532067A5 (OSRAM) | ||
| JP2018515434A5 (OSRAM) | ||
| JP2016509047A5 (OSRAM) | ||
| JP2014520108A5 (OSRAM) | ||
| JP2010535180A5 (OSRAM) | ||
| JP2012509349A5 (OSRAM) | ||
| WO2018075959A4 (en) | Methods using hdac11 inhibitors | |
| WO2016141042A4 (en) | Novel compositions, uses and methods for making them | |
| WO2014168523A4 (ru) | Производные бисамидов дикарбоновых кислот, их применение, фармацевтическая композиция на их основе, способы их получения | |
| JP2017511321A5 (OSRAM) | ||
| JP2020527173A5 (OSRAM) | ||
| JP2019530724A5 (OSRAM) | ||
| JP2013542267A5 (OSRAM) | ||
| JP2018530582A5 (OSRAM) |